BiotechTube

eFT508

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer

Trial Timeline

Dec 3, 2015 → Mar 22, 2019

NCT ID
NCT02605083

About eFT508

eFT508 is a phase 1/2 stage product being developed by eFFECTOR Therapeutics for Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02605083. Target conditions include Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT03690141Phase 2Terminated
NCT03318562Phase 2Terminated
NCT02605083Phase 1/2Terminated

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
E7389EisaiPhase 1
33
VeliparibAbbViePhase 2
52
AK-105AkesoPhase 1
32
XL820ExelixisPhase 1
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
LY3300054 + PrexasertibEli LillyPhase 1
33
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
NBTXR3NanobiotixPhase 1/2
36

Other Products from eFFECTOR Therapeutics

Alpelisib + Tamoxifen + Zotatifin + FulvestrantPhase 2
44
eFT508Phase 2
44
eFT508Phase 2
44
eFT508 + AvelumabPhase 2
44
Tomivosertib (eFT-508)Phase 2
44